Clinical trials are operationally burdensome. Regulatory requirements are expected, but unclear. The importance of biospecimens is increasing, and regulatory risk grows with biospecimen importance. In this presentation, Slope's Chief Clinical Officer, Hope Meely, explains the many hidden regulatory risks in biospecimen management, and shares key strategies to achieve proactive regulatory risk-proofing.